Starts & Stops: Small Innovators Advance Bioresorbable Stents
Executive Summary
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions, and suspensions over the last month. This edition, which looks at trial updates from Oct. 5 through to Nov. 4, highlights the small innovators developing bioresorbable stents for cardio- and peripheral vascular disease.
You may also be interested in...
Starts & Stops: Corlife's Decellularized Human Pulmonary Valve Shows Early Promise
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. News about trials of cardiovascular devices, especially novel heart valve replacement technologies, lead this month's edition, covering mid-May through mid-June.
TCT Round-Up: The Next Generation Of Drug-Eluting Stents, Drug-Coated Balloon Featured At Washington Conference
One of the world’s largest showcases for new interventional cardiology technology, the 2016 Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific sessions, were held Oct. 29-Nov. 2 in Washington, DC. This year’s edition of TCT featured many presentations on new drug-eluting coronary stent technologies, as well as drug-coated balloons for peripheral interventions.
TCT 2016: Three-Year ABSORB II Data Fail To Show The Hoped-For Long-Term Benefit Of Bioresorbable Stent
The data, presented Oct. 30 at the TCT Conference in Washington, DC, also showed higher rates of device-related adverse events including myocardial infarction with Abbott’s Absorb bioresorbable stent than a metallic drug-eluting stent, but the study was not powered to show differences in clinical endpoints, so this adverse safety signal must be evaluated in future clinical trials.